Immuron Limited (ASX:IMC)

Market Cap	12.09M -37.4%
Revenue (ttm)	7.48M +14.3%
Net Income	-4.65M
EPS	-0.02
Shares Out	326.65M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	145,506
Open	0.0360
Previous Close	0.0370
Day's Range	0.0360 - 0.0420
52-Week Range	0.0260 - 0.0980
Beta	0.51
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Immuron

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive func...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 7
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IMC

Financial Performance

In fiscal year 2025, Immuron's revenue was 7.29 million, an increase of 48.63% compared to the previous year's 4.90 million. Losses were -5.22 million, -24.81% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 26, 2026

Data Sources Report a data error